STOCK TITAN
  1. Home
  2. Sec-filings
  3. FOLD
  4. [Form 4] AMICUS THERAPEUTICS, INC. Insider Trading Activity

Amicus Therapeutics (FOLD) CEO sells 75K shares in planned trade

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Amicus Therapeutics President and CEO Bradley L. Campbell reported an option exercise and share sale. On January 20, 2026, he exercised 75,000 stock options with an exercise price of $6.10 per share, receiving 75,000 shares of common stock. That same day, he sold 75,000 shares of common stock at a weighted average price of $14.3091 per share, with individual sale prices ranging from $14.30 to $14.32.

Following these transactions, Campbell directly owned 1,021,180 shares of Amicus Therapeutics common stock. All options exercised were fully vested and exercisable as of the transaction date. The filing notes that all transactions were carried out under a Rule 10b5-1 trading plan adopted on September 12, 2025.

Positive

  • None.

Negative

  • None.
Insider Campbell Bradley L
Role President and CEO
Sold 75,000 shs ($1.07M)
Type Security Shares Price Value
Exercise Stock Options (right to buy) 75,000 $0.00 --
Exercise Common Stock 75,000 $6.10 $458K
Sale Common Stock 75,000 $14.3091 $1.07M
Holdings After Transaction: Stock Options (right to buy) — 0 shares (Direct); Common Stock — 1,096,180 shares (Direct)
Footnotes (1)
  1. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.30 to $14.32 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. All of the options were fully vested and exercisable as of the transaction date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Campbell Bradley L
(Last) (First) (Middle)
47 HULFISH STREET
(Street)
PRINCETON NJ 08542
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AMICUS THERAPEUTICS, INC. [ FOLD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/20/2026 M 75,000 A $6.1 1,096,180 D
Common Stock 01/20/2026 S 75,000 D $14.3091(1) 1,021,180 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (right to buy) $6.1 01/20/2026 M 75,000 (2) 06/15/2026 Common Stock 75,000 $0 0 D
Explanation of Responses:
1. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.30 to $14.32 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. All of the options were fully vested and exercisable as of the transaction date.
Remarks:
All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025.
/s/ Christian Formica, Attorney-in-Fact 01/22/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Amicus Therapeutics (FOLD) report for January 20, 2026?

Amicus Therapeutics reported that President and CEO Bradley L. Campbell exercised 75,000 stock options at $6.10 per share and sold 75,000 shares of common stock at a weighted average price of $14.3091 on January 20, 2026.

How many Amicus Therapeutics shares does CEO Bradley L. Campbell own after this Form 4?

After the reported transactions, Bradley L. Campbell directly owned 1,021,180 shares of Amicus Therapeutics common stock.

Were the Amicus Therapeutics options fully vested before the CEO exercised them?

Yes. The filing states that all of the options were fully vested and exercisable as of the January 20, 2026 transaction date.

What prices were received for the Amicus Therapeutics shares sold by the CEO?

The weighted average sale price was $14.3091 per share, with individual sale prices ranging from $14.30 to $14.32 per share.

Was the Amicus Therapeutics CEO’s stock sale made under a Rule 10b5-1 trading plan?

Yes. The filing notes that all transactions reported were effected pursuant to a Rule 10b5-1 trading plan adopted by Bradley L. Campbell on September 12, 2025.

What derivative security did the Amicus Therapeutics CEO exercise in this Form 4?

He exercised 75,000 stock options (right to buy) with a $6.10 exercise price, which were fully vested and exercisable as of the transaction date and resulted in 0 derivative options remaining afterward.